About Us

MISSION STATEMENT: The HIV+Hepatitis Policy Institute promotes quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions.

Monitors policies that impact the prevention and treatment of HIV, viral hepatitis, and other health conditions in the United States.

Communicates with members of the HIV, hepatitis, and other patient group communities on key policy issues that impact their access to healthcare.

Educates policymakers and members of the media about efforts to end both HIV and hepatitis in the United States and to improve access to quality and affordable healthcare for people with or at risk of serious or chronic health conditions.

Our Team

CARL SCHMID

Executive Director, HIV+Hepatitis Policy Institute, Washington, D.C.

cschmid@hivhep.org

Carl Schmid has been a national policy and advocacy leader in the HIV community for over 20 years.  He spent 16 years with The AIDS Institute, serving as its Deputy Executive Director. In December 2019, he formed the HIV+Hepatitis Policy Institute, which promotes quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions.

Mr. Schmid leads advocacy efforts to ensure domestic HIV and hepatitis programs are based on sound public policy and fully funded. He has expertise in healthcare financing systems, including Medicaid and Medicare, and leads efforts to ensure that the Affordable Care Act meets the needs of beneficiaries, including prescription medications.

From December 2018 to August 2021 he served as Co-Chair of the Presidential Advisory Council on HIV/AIDS (PACHA). He currently serves as a member of PACHA and as a consumer representative to the National Association of Insurance Commissioners. 

He is a cancer survivor and living with chronic hepatitis B.

Mr. Schmid earned a B.A. in Public Affairs and an M.B.A. in International Affairs from the George Washington University in Washington, D.C.

Scott Palmer

Executive Assistant

spalmer@hivhep.org

Ann Lefert

The Lefert Group

Policy Consultant

ann@thelefertgroup.com

Jennifer Burke

Communications Consultant

jburke@hivhep.org

Board Members

CARL SCHMID

President

Executive Director

HIV+Hep Policy Institute

Washington, DC

REKHA RAMESH

Treasurer 

Vice President, Head of Global Policy

Gilead Sciences, Inc.

Foster City, CA

JUSTIN C. SMITH MS, MPH

Secretary

Director, Campaign to End AIDS

Positive Impact Health Centers

Atlanta, GA

ERIN DARLING

Associate Vice President of Federal Policy

Merck

Washington, DC

MARC MEACHEM

Director of External Affairs

ViiV Healthcare

Washington, DC

RAFAELÉ NARVÁEZ

Co-Founder

Latinos Salud

Oakland Park, FL

ANDREW SPERLING

Mental Health Advocate 

Arlington, VA

PAM TRAXEL

Senior Vice President

American Cancer Society

Cancer Action Network

Washington, DC

STEVEN R. YOUNG

Former Director

HIV/AIDS Bureau, HRSA, HHS

Yardley, PA

Funders for HIV+Hepatitis Policy Institute

HIV+Hep appreciates the support of numerous funders, and recognizes those below that are our corporate members and sponsors:

Get Involved

Facebook posts by @HIV+Hep

Tweets by @HIV+Hep

@HIVHep’s Carl Schmid in @HIVGov: “[W]e now have nat’l strategic plans to end several infectious diseases including viral #hepatitis, #HIV, & STIs. A strength included in all the plans is taking a syndemic approach to these often intersecting epidemics”: https://t.co/9tAbjjeq0u https://t.co/qqVgrHBVCJ HIVHep photo
Q&A with Antonio Ciaccia of 3 Axis Advisors: ‘PBMs aren’t really PBMs anymore’ https://t.co/WC7KFp220w
@HIVHep joined 140+ groups to send a letter to @RepMcEachin & @RodneyDavis thanking them for introducing the HELP Copays Act #HR5801. This critical bill will remove barriers to treatment for some of the most vulnerable Americans by making #AllCopaysCount: https://t.co/ZbDXsRYUtt https://t.co/jxtEDdYyoM HIVHep photo
Speaking to @MHExecutive @HIVHep’s Carl Schmid considers how to overcome barriers to #PrEP usage including better education and testing, making sure #PrEP is offered by providers free of charge, and overcoming the stigma still attached to #HIV: https://t.co/3EBcOizIFB. https://t.co/ZEfejHdOzV HIVHep photo
From @medpagetoday: “Copay assistance progs are important to #patients w/ #chronicillness, @HIVHep’s Carl Schmid said. For example, ‘ #HIV #Rx & #hepatitis #Rx are costly & usually on specialty tiers… & more & more people are in high-deductible plans”: https://t.co/3qHIojqE25 https://t.co/axemWU1zrx HIVHep photo

Pin It on Pinterest

Share This